Trial Outcomes & Findings for Online Treatment of Cognitive Impairment and Insomnia in Cancer Survivors (NCT NCT04026048)

NCT ID: NCT04026048

Last Updated: 2025-04-06

Results Overview

The FACT-Cog was used to measure perceived cognitive impairment (PCI). It is a 37-item questionnaire with four cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from others, and perceived cognitive abilities. Responses range from 0, ''never,'' to 4, ''several times a day,'' in the previous 7 days and negatively worded items are reverse scored to create subscale scores. Scores on the PCI subscale can range from 0 to 72 points, with a higher score indicative of better self-reported cognitive functioning and quality of life. A change of 5.9-points has been established as clinically meaningful change on the FACT-Cog PCI subscale

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

132 participants

Primary outcome timeframe

Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Results posted on

2025-04-06

Participant Flow

Participant milestones

Participant milestones
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Pre-treatment to Treatment Completion
STARTED
63
69
Pre-treatment to Treatment Completion
COMPLETED
58
63
Pre-treatment to Treatment Completion
NOT COMPLETED
5
6
3 Month Follow-up
STARTED
58
63
3 Month Follow-up
COMPLETED
55
60
3 Month Follow-up
NOT COMPLETED
3
3
6 Month Follow-up
STARTED
55
60
6 Month Follow-up
COMPLETED
53
59
6 Month Follow-up
NOT COMPLETED
2
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Online Treatment of Cognitive Impairment and Insomnia in Cancer Survivors

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Total
n=132 Participants
Total of all reporting groups
Age, Continuous
59.21 years
STANDARD_DEVIATION 11.93 • n=99 Participants
61.25 years
STANDARD_DEVIATION 10.60 • n=107 Participants
60.28 years
STANDARD_DEVIATION 11.26 • n=206 Participants
Sex: Female, Male
Female
50 Participants
n=99 Participants
52 Participants
n=107 Participants
102 Participants
n=206 Participants
Sex: Female, Male
Male
13 Participants
n=99 Participants
17 Participants
n=107 Participants
30 Participants
n=206 Participants
Race/Ethnicity, Customized
White
57 Participants
n=99 Participants
65 Participants
n=107 Participants
122 Participants
n=206 Participants
Race/Ethnicity, Customized
BIPOC
6 Participants
n=99 Participants
4 Participants
n=107 Participants
10 Participants
n=206 Participants
Region of Enrollment
Canada
63 participants
n=99 Participants
69 participants
n=107 Participants
132 participants
n=206 Participants
Years of education
High school (≤11 years)
4 Participants
n=99 Participants
2 Participants
n=107 Participants
6 Participants
n=206 Participants
Years of education
College (12-14 years)
18 Participants
n=99 Participants
24 Participants
n=107 Participants
42 Participants
n=206 Participants
Years of education
Postsecondary (≥15 years)
41 Participants
n=99 Participants
43 Participants
n=107 Participants
84 Participants
n=206 Participants
Employment status
Not working/retired
36 Participants
n=99 Participants
48 Participants
n=107 Participants
84 Participants
n=206 Participants
Employment status
Working (part or full-time)
27 Participants
n=99 Participants
21 Participants
n=107 Participants
48 Participants
n=206 Participants
Cancer type
Breast
25 Participants
n=99 Participants
29 Participants
n=107 Participants
54 Participants
n=206 Participants
Cancer type
Prostate and male genitourinary
2 Participants
n=99 Participants
5 Participants
n=107 Participants
7 Participants
n=206 Participants
Cancer type
Female genitourinary
6 Participants
n=99 Participants
5 Participants
n=107 Participants
11 Participants
n=206 Participants
Cancer type
GI tract
2 Participants
n=99 Participants
5 Participants
n=107 Participants
7 Participants
n=206 Participants
Cancer type
Hematologic
11 Participants
n=99 Participants
5 Participants
n=107 Participants
16 Participants
n=206 Participants
Cancer type
Skin
2 Participants
n=99 Participants
6 Participants
n=107 Participants
8 Participants
n=206 Participants
Cancer type
Other
4 Participants
n=99 Participants
2 Participants
n=107 Participants
6 Participants
n=206 Participants
Cancer type
Multiple types
11 Participants
n=99 Participants
12 Participants
n=107 Participants
23 Participants
n=206 Participants
Time since cancer diagnosis (years)
<2
7 Participants
n=99 Participants
7 Participants
n=107 Participants
14 Participants
n=206 Participants
Time since cancer diagnosis (years)
2-4
11 Participants
n=99 Participants
21 Participants
n=107 Participants
32 Participants
n=206 Participants
Time since cancer diagnosis (years)
5-9
17 Participants
n=99 Participants
14 Participants
n=107 Participants
31 Participants
n=206 Participants
Time since cancer diagnosis (years)
≥10
28 Participants
n=99 Participants
26 Participants
n=107 Participants
54 Participants
n=206 Participants
Cancer stage
Stage 0/in situ
1 Participants
n=99 Participants
3 Participants
n=107 Participants
4 Participants
n=206 Participants
Cancer stage
Stage I
12 Participants
n=99 Participants
15 Participants
n=107 Participants
27 Participants
n=206 Participants
Cancer stage
Stage II
13 Participants
n=99 Participants
10 Participants
n=107 Participants
23 Participants
n=206 Participants
Cancer stage
Stage III
15 Participants
n=99 Participants
13 Participants
n=107 Participants
28 Participants
n=206 Participants
Cancer stage
Stage IV
2 Participants
n=99 Participants
5 Participants
n=107 Participants
7 Participants
n=206 Participants
Cancer stage
Unknown/not applicable
20 Participants
n=99 Participants
23 Participants
n=107 Participants
43 Participants
n=206 Participants
Cancer treatments received
Surgery
52 Participants
n=99 Participants
65 Participants
n=107 Participants
117 Participants
n=206 Participants
Cancer treatments received
Chemotherapy
46 Participants
n=99 Participants
35 Participants
n=107 Participants
81 Participants
n=206 Participants
Cancer treatments received
Radiation
38 Participants
n=99 Participants
38 Participants
n=107 Participants
76 Participants
n=206 Participants
Cancer treatments received
Hormone therapy
13 Participants
n=99 Participants
29 Participants
n=107 Participants
42 Participants
n=206 Participants
Cancer treatments received
Other
4 Participants
n=99 Participants
4 Participants
n=107 Participants
8 Participants
n=206 Participants
Time since insomnia began (months)
99.19 months
STANDARD_DEVIATION 71.17 • n=99 Participants
88.56 months
STANDARD_DEVIATION 79.23 • n=107 Participants
93.63 months
STANDARD_DEVIATION 75.39 • n=206 Participants
Baseline insomnia score
17.27 units on a scale
STANDARD_DEVIATION 3.53 • n=99 Participants
17.88 units on a scale
STANDARD_DEVIATION 3.83 • n=107 Participants
17.59 units on a scale
STANDARD_DEVIATION 3.69 • n=206 Participants
Baseline perceived cognitive impairment score
39.40 units on a scale
STANDARD_DEVIATION 12.32 • n=99 Participants
38.80 units on a scale
STANDARD_DEVIATION 13.86 • n=107 Participants
39.1 units on a scale
STANDARD_DEVIATION 13.10 • n=206 Participants

PRIMARY outcome

Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

The FACT-Cog was used to measure perceived cognitive impairment (PCI). It is a 37-item questionnaire with four cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from others, and perceived cognitive abilities. Responses range from 0, ''never,'' to 4, ''several times a day,'' in the previous 7 days and negatively worded items are reverse scored to create subscale scores. Scores on the PCI subscale can range from 0 to 72 points, with a higher score indicative of better self-reported cognitive functioning and quality of life. A change of 5.9-points has been established as clinically meaningful change on the FACT-Cog PCI subscale

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
Baseline
39.39 score on a scale
Standard Deviation 12.32
38.79 score on a scale
Standard Deviation 13.85
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
4 weeks
48.28 score on a scale
Standard Deviation 11.89
44.71 score on a scale
Standard Deviation 13.84
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
8 weeks
53.44 score on a scale
Standard Deviation 12.01
43.00 score on a scale
Standard Deviation 12.89
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
3 months follow-up
53.16 score on a scale
Standard Deviation 11.37
46.21 score on a scale
Standard Deviation 19.64
The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) Version 3
6 months follow-up
52.47 score on a scale
Standard Deviation 12.89
51.46 score on a scale
Standard Deviation 14.10

SECONDARY outcome

Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

The ISI is designed to specifically assess the severity of insomnia symptoms, the impact on daytime functioning, and the amount of associated distress. The ISI has 7 questions, which are summed to compute a total score. The range of the ISI is 0-28 with the higher the value, the more severe the insomnia severity.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
The Insomnia Severity Index (ISI)
Basline
17.27 score on Insomnai Severity Index
Standard Deviation 3.53
15.06 score on Insomnai Severity Index
Standard Deviation 4.57
The Insomnia Severity Index (ISI)
4 weeks
9.67 score on Insomnai Severity Index
Standard Deviation 4.01
9.77 score on Insomnai Severity Index
Standard Deviation 4.81
The Insomnia Severity Index (ISI)
8 weeks
6.03 score on Insomnai Severity Index
Standard Deviation 3.90
6.34 score on Insomnai Severity Index
Standard Deviation 4.30
The Insomnia Severity Index (ISI)
3 months follow-up
7.11 score on Insomnai Severity Index
Standard Deviation 4.84
6.37 score on Insomnai Severity Index
Standard Deviation 4.60
The Insomnia Severity Index (ISI)
6 months follow-up
7.94 score on Insomnai Severity Index
Standard Deviation 5.60
6.28 score on Insomnai Severity Index
Standard Deviation 4.23

SECONDARY outcome

Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.

Sleep efficiency is the percentage of time spent asleep while in bed. It is calculated by dividing the amount of time spent asleep (in minutes) by the total amount of time in bed (in minutes). The unit of measure is a percentage and is averaged over the whole week for the total sleep efficiency score.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
4 weeks
87.18 percentage of sleep efficiency
Standard Deviation 8.17
88.10 percentage of sleep efficiency
Standard Deviation 6.24
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
Baseline
73.22 percentage of sleep efficiency
Standard Deviation 12.45
74.03 percentage of sleep efficiency
Standard Deviation 13.58
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
8 weeks
89.63 percentage of sleep efficiency
Standard Deviation 7.10
89.33 percentage of sleep efficiency
Standard Deviation 6.41
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
3 month follow-up
88.58 percentage of sleep efficiency
Standard Deviation 8.02
87.22 percentage of sleep efficiency
Standard Deviation 7.62
Sleep Efficiency Measured by The Consensus Sleep Diary (CSD)
6 month follow-up
88.52 percentage of sleep efficiency
Standard Deviation 7.88
87.83 percentage of sleep efficiency
Standard Deviation 6.81

SECONDARY outcome

Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.

The sleep diary will be used to calculate sleep-onset latency, which is the length of time that it takes to accomplish the transition from full wakefulness to sleep. The unit of measure is minutes and is averaged over the whole week for the total sleep onset latency score.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
Baseline
40.56 minutes
Standard Deviation 32.40
41.48 minutes
Standard Deviation 34.22
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
4 weeks
16.68 minutes
Standard Deviation 15.73
16.98 minutes
Standard Deviation 13.43
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
8 weeks
12.68 minutes
Standard Deviation 8.98
15.41 minutes
Standard Deviation 11.7
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
3 month follow-up
16.70 minutes
Standard Deviation 18.44
21.43 minutes
Standard Deviation 16.04
Sleep-onset Latency Measured by The Consensus Sleep Diary (CSD)
6 month follow-up
14.71 minutes
Standard Deviation 10.41
22.26 minutes
Standard Deviation 20.24

SECONDARY outcome

Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.

The sleep diary will be used to calculate wake after sleep onset, which refers to periods of wakefulness occurring after defined sleep onset. The score is reported in minutes and is averaged over the whole week for the total wake after sleep onset.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
6 month follow-up
21.46 minutes
Standard Deviation 20.24
21.85 minutes
Standard Deviation 20.34
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
Baseline
63.29 minutes
Standard Deviation 41.99
50.80 minutes
Standard Deviation 34.14
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
4 weeks
23.32 minutes
Standard Deviation 17.30
19.90 minutes
Standard Deviation 14.87
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
8 weeks
21.84 minutes
Standard Deviation 19.80
20.06 minutes
Standard Deviation 18.95
Wake After Sleep Onset Measured by The Consensus Sleep Diary (CSD)
3 month follow-up
20.06 minutes
Standard Deviation 20.46
22.87 minutes
Standard Deviation 19.86

SECONDARY outcome

Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose consensus sleep diaries were complete and returned.

The sleep diary will be used to calculate total sleep time. The score is reported in minutes and is averaged over the whole week for the total sleep time.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
Baseline
370.06 minutes
Standard Deviation 67.72
378.41 minutes
Standard Deviation 81.09
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
4 weeks
358.77 minutes
Standard Deviation 64.05
376.08 minutes
Standard Deviation 59.71
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
8 weeks
392.14 minutes
Standard Deviation 52.52
406.40 minutes
Standard Deviation 57.11
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
3 month follow-up
412.06 minutes
Standard Deviation 68.69
418.81 minutes
Standard Deviation 62.12
Total Sleep Time Measured by The Consensus Sleep Diary (CSD):
6 month follow-up
401.42 minutes
Standard Deviation 84.67
429.24 minutes
Standard Deviation 56.60

SECONDARY outcome

Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

Anxiety and Depression will be measured using the HADS, which is a 14-item, self-rated instrument for anxiety (7 items) and depression (7 items) symptoms in the past week and has been extensively used in people with cancer. Scores range from 0-21 with below 7 indicating a non-case and the higher the score indicates greater symptom severity.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Hospital Anxiety and Depression Scale (HADS)
Baseline depression
7.90 score on a scale
Standard Deviation 2.88
6.39 score on a scale
Standard Deviation 3.72
Hospital Anxiety and Depression Scale (HADS)
4 weeks depression
4.45 score on a scale
Standard Deviation 3.48
4.63 score on a scale
Standard Deviation 3.65
Hospital Anxiety and Depression Scale (HADS)
8 weeks depression
3.14 score on a scale
Standard Deviation 3.29
3.09 score on a scale
Standard Deviation 3.14
Hospital Anxiety and Depression Scale (HADS)
3 month follow-up depression
3.57 score on a scale
Standard Deviation 2.88
5.90 score on a scale
Standard Deviation 2.36
Hospital Anxiety and Depression Scale (HADS)
6 month follow-up depression
4.24 score on a scale
Standard Deviation 3.52
3.30 score on a scale
Standard Deviation 2.99
Hospital Anxiety and Depression Scale (HADS)
Baseline anxiety
9.33 score on a scale
Standard Deviation 3.48
8.70 score on a scale
Standard Deviation 4.24
Hospital Anxiety and Depression Scale (HADS)
4 weeks anxiety
6.88 score on a scale
Standard Deviation 3.25
7.97 score on a scale
Standard Deviation 3.78
Hospital Anxiety and Depression Scale (HADS)
8 weeks anxiety
5.89 score on a scale
Standard Deviation 3.31
7.08 score on a scale
Standard Deviation 4.47
Hospital Anxiety and Depression Scale (HADS)
3 month follow-up anxiety
6.04 score on a scale
Standard Deviation 3.79
5.97 score on a scale
Standard Deviation 4.41
Hospital Anxiety and Depression Scale (HADS)
6 month follow-up anxiety
6.18 score on a scale
Standard Deviation 4.33
5.67 score on a scale
Standard Deviation 3.82

SECONDARY outcome

Timeframe: Change from Baseline to Week 4, Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

Fatigue will be measured using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), which is a 30 item self-report measure comprised of five subscales (general, emotional, physical, mental, vigor) and a total fatigue score. Each subscale score ranges from 0 to 24. The Total MSFI-SF score is calculated by adding the general, physical, emotional and mental subscale scores and subtracting vigor subscale score. Total MFSI-SF score ranges from -24 to 96 with a higher score indicating higher levels of cancer-related fatigue experienced by the patient.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
Baseline
29.57 score on a scale
Standard Deviation 16.75
26.64 score on a scale
Standard Deviation 19.38
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
4 weeks
16.52 score on a scale
Standard Deviation 17.50
17.17 score on a scale
Standard Deviation 20.49
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
8 weeks
4.72 score on a scale
Standard Deviation 16.17
6.05 score on a scale
Standard Deviation 19.62
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
3 month follow-up
9.13 score on a scale
Standard Deviation 16.44
6.79 score on a scale
Standard Deviation 18.41
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
6 month follow-up
10.04 score on a scale
Standard Deviation 18.13
5.95 score on a scale
Standard Deviation 17.65

SECONDARY outcome

Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

The Hopkins Verbal Learning Test-Revised (HVLT-R) is a brief assessment of verbal learning and memory (immediate recall, delayed recall, delayed recognition). When scoring the HVLT-R, the three learning trials are combined to calculate a total recall score; the delayed recall trial creates the delayed recall score; the retention (%) score is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. These scores are then converted to an age-based T score (Mean=50, SD=10). Higher scores represent better verbal learning and memory.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
The Hopkins Verbal Learning Test-Revised (HVLT-R)
Baseline
49.84 t score
Standard Deviation 10.72
49.22 t score
Standard Deviation 12.64
The Hopkins Verbal Learning Test-Revised (HVLT-R)
8 weeks
49.11 t score
Standard Deviation 11.63
50.19 t score
Standard Deviation 10.95
The Hopkins Verbal Learning Test-Revised (HVLT-R)
3 month follow-up
54.25 t score
Standard Deviation 9.66
53.36 t score
Standard Deviation 11.47
The Hopkins Verbal Learning Test-Revised (HVLT-R)
6 month follow-up
55.94 t score
Standard Deviation 10.67
54.54 t score
Standard Deviation 10.94

SECONDARY outcome

Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

The COWAT is a measure of verbal fluency, cognitive and motor speed, cognitive flexibility, strategy utilization, suppression of interference, and response inhibition. The total score is the total number of different words produced for all three letters in a timeframe of 3 minutes (1 minute for each letter). The scores are adjusted based on age and education level. A greater score indicates better verbal fluency. A score less then 33 indicates below average performance, scores between 34 and 45 indicate average performance, and scores greater than 45 are above average, with scores greater than 52 indicate superior performance. A minimum score is 0 (no words produced) and there is no set maximum score, as it depends on how many words can be produced in the given time frame.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
The Controlled Oral Word Association Test (COWAT)
Baseline
47.14 adj score on a scale
Standard Deviation 11.48
44.41 adj score on a scale
Standard Deviation 12.31
The Controlled Oral Word Association Test (COWAT)
3 month follow-up
51.04 adj score on a scale
Standard Deviation 12.91
48.42 adj score on a scale
Standard Deviation 12.20
The Controlled Oral Word Association Test (COWAT)
8 weeks
46.77 adj score on a scale
Standard Deviation 11.12
47.50 adj score on a scale
Standard Deviation 13.61
The Controlled Oral Word Association Test (COWAT)
6 month follow-up
50.02 adj score on a scale
Standard Deviation 11.44
49.62 adj score on a scale
Standard Deviation 13.87

SECONDARY outcome

Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scale (WMS). Part A of digit span (the forward span) captures attention efficiency and capacity, and part B (the backward span) is an executive task dependent on working memory. The Digit Span subtest will be scored as one summary value. The unit of measure is the total recall. Scores on this measure range from 0-48, where greater scores indicates greater attention efficiency, capacity and working memory.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
The Digit Span
Baseline
28.49 score on a scale
Standard Deviation 4.06
28.44 score on a scale
Standard Deviation 5.03
The Digit Span
8 weeks
30.11 score on a scale
Standard Deviation 4.82
27.97 score on a scale
Standard Deviation 5.15
The Digit Span
3 month follow-up
30.73 score on a scale
Standard Deviation 4.97
28.17 score on a scale
Standard Deviation 6.14
The Digit Span
6 month follow-up
31.13 score on a scale
Standard Deviation 4.38
28.38 score on a scale
Standard Deviation 5.72

SECONDARY outcome

Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A) is composed of 75 items within nine non-overlapping theoretically and empirically derived clinical scales. It has 2 broad indexes (Behavioural Regulation and Metacognition), an overall summary score, and three validity scales. This analysis examines the overall summary score. T scores (M = 50, SD = 10; transformations of the raw scale scores) are used to interpret the individual's level of executive functioning. Traditionally, T scores at or above 65 are considered clinically significant. Greater scores indicate greater deficits in executive functioning.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
Baseline
60.37 t score
Standard Deviation 10.31
59.13 t score
Standard Deviation 11.28
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
8 weeks
51.14 t score
Standard Deviation 10.72
52.41 t score
Standard Deviation 11.30
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
3 month follow-up
50.13 t score
Standard Deviation 10.67
51.54 t score
Standard Deviation 11.08
The Behaviour Rating Inventory of Executive Function-Adult (BRIEF-A)
6 month follow-up
50.65 t score
Standard Deviation 10.39
52.54 t score
Standard Deviation 13.60

SECONDARY outcome

Timeframe: Change from Baseline to Week 8, 3 month follow up, 6 month follow up

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

The WPAI questionnaire was developed for the purpose of collecting productivity loss data within clinical trials and is suitable for direct translation into a monetary figure. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
The Work Productivity and Activity Impairment (WPAI)
3 month follow-up
6.25 percentage of work productivity loss
Standard Deviation 20.14
5.85 percentage of work productivity loss
Standard Deviation 20.37
The Work Productivity and Activity Impairment (WPAI)
Baseline
23.33 percentage of work productivity loss
Standard Deviation 34.04
18.28 percentage of work productivity loss
Standard Deviation 31.29
The Work Productivity and Activity Impairment (WPAI)
8 weeks
7.42 percentage of work productivity loss
Standard Deviation 21.48
11.54 percentage of work productivity loss
Standard Deviation 28.05
The Work Productivity and Activity Impairment (WPAI)
6 month follow-up
5.77 percentage of work productivity loss
Standard Deviation 19.36
5.63 percentage of work productivity loss
Standard Deviation 19.92

SECONDARY outcome

Timeframe: Baseline

Population: Although there were 63 and 69 participants who began treatment in the CBT-I and waitlist groups, respectively, we only have data from participants whose data were complete for this measure.

The Credibility/Expectancy Questionnaire (CEQ) is a 6-item questionnaire that captures both credibility beliefs and outcome expectancy. Questions on this scale are rated on a 1-to-9 point or 0-100% Likert scale, depending on the exact question. The scale was adapted to separately assess: (1) credibility beliefs for insomnia; (2) credibility beliefs for PCI; (3) expectancy beliefs for insomnia; and (4) expectancy beliefs for PCI. Since the CEQ utilizes two scales during the administration (1-9, and 0-100%), a composite score was derived for each factor (expectancy and credibility) by first standardizing the individual items and then summing those items for each factor yielding total scores, where higher values indicate stronger credibility and expectancy beliefs. Credibility beliefs scores ranged from 0 to 23 and expectancy beliefs scores ranged from 0 to 27.

Outcome measures

Outcome measures
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 Participants
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 Participants
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Credibility/Expectancy Questionnaire (CEQ)
Baseline credibility
15.37 scores on a scale
Standard Deviation 4.42
16.43 scores on a scale
Standard Deviation 3.94
Credibility/Expectancy Questionnaire (CEQ)
Baseline expectancy
19.68 scores on a scale
Standard Deviation 4.48
20.28 scores on a scale
Standard Deviation 4.19

Adverse Events

Cognitive Behaviour Therapy for Insomnia (CBT-I)

Serious events: 2 serious events
Other events: 12 other events
Deaths: 0 deaths

Waitlist Control Group

Serious events: 2 serious events
Other events: 14 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 participants at risk
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 participants at risk
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
General disorders
Infection
1.6%
1/63 • Number of events 1 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
1.4%
1/69 • Number of events 1 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
General disorders
Surgery
1.6%
1/63 • Number of events 1 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
1.4%
1/69 • Number of events 1 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.

Other adverse events

Other adverse events
Measure
Cognitive Behaviour Therapy for Insomnia (CBT-I)
n=63 participants at risk
Participants will receive individualized CBT-I delivered by video-conferencing over the course of eight weeks. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
Waitlist Control Group
n=69 participants at risk
Participants in the waitlist control group will be required to monitor their sleep with sleep diaries for 7 weeks. They will receive CBT-I delivered by video-conferencing immediately after the waiting period. Cognitive Behaviour Therapy for Insomnia (CBT-I): CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
General disorders
Headache or Migraine
6.3%
4/63 • Number of events 4 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
2.9%
2/69 • Number of events 2 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
General disorders
Increased Pain
7.9%
5/63 • Number of events 5 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
10.1%
7/69 • Number of events 7 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
General disorders
Fatigue
4.8%
3/63 • Number of events 3 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.
7.2%
5/69 • Number of events 5 • 6 months
We followed the CONSORT 2022 guidelines for reporting harms 33 to ensure that adverse events (AEs) were: (1) Clearly defined; (2) Clearly stated in measurement and methodology; (3) Reported with an attribution; (4) Reported with severity. Participants were asked about five categories of possible AEs: (1) Distress, illness, or incidents; (2) New development of symptoms; (3) Unplanned medical visits/procedures; (4) Unplanned need to take medication; (5) Any other physical/mental health concern.

Additional Information

Dr. Sheila Garland

Memorial University of Newfoundland

Phone: (709) 864-4897

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place